ArriVent BioPharma, Inc.
Close on Oct 19, 2026
- Market cap
- $854.07M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 5, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 3, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | After market close | – | – | – |
Press releases
Announcements ArriVent BioPharma filed with the SEC
ArriVent Announces First Patient Dosed with
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ArriVent Announces Program Update from the Phase
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ArriVent BioPharma Reports Second Quarter 2026
Material agreement · Results of operations · EX-99.1 to Form 8-K
ArriVent BioPharma Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ArriVent BioPharma Reports Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
ArriVent BioPharma Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ArriVent BioPharma Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20
Other events · EX-99.1 to Form 8-K
Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
Material agreement · Other events · EX-99.1 to Form 8-K
Arrivent Announces Positive Interim Firmonertinib
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ArriVent BioPharma Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
ArriVent BioPharma Appoints Merdad Parsey, M.D.,
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
ArriVent BioPharma Reports Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
ArriVent BioPharma Enters Exclusive License
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
ArriVent BioPharma Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ArriVent BioPharma Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
a Multi-Target ADC Collaboration with Alphamab
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
ArriVent BioPharma Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
ArriVent Biopharma Reports Full Year 2023 Financial
Results of operations · EX-99.1 to Form 8-K